Vanderbilt University:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C3463)
◆英語タイトル:Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3463
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年8月
◆ページ数:78
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Vanderbilt University (Vanderbilt) is a medical and research university that provides professional degrees. The university offers graduate and undergraduate degrees in the fields of engineering, music, liberal arts and sciences, education and human development. It provides services such as clinical research and research support services. Vanderbilt’s research support services includes cutting edge research, liberal arts education, nationally recognized schools of law, business, medicine, and nursing and divinity. The university offers its services through blair school of music, divinity school, school of engineering, law school, graduate school, school of medicine, and others. Vanderbilt is headquartered in Nashville, Tennessee, the US.

Vanderbilt University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vanderbilt University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vanderbilt University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vanderbilt University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vanderbilt University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vanderbilt University, Medical Devices Deals, 2012 to YTD 2018 10
Vanderbilt University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Vanderbilt University, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Deerfield Management and Vanderbilt University Form Joint Venture 13
Boehringer Ingelheim Enters into Agreement with Vanderbilt University 14
Bayer and Vanderbilt University Medical Center Enter into Research Agreement 15
Cancer Prevention Pharma Enters into Partnership with National Cancer Institute and Vanderbilt University Medical Center 16
Human Vaccines Project and Vanderbilt University Medical Center Enters into Agreement with Illumina 17
Boehringer Ingelheim Enters into Agreement with Vanderbilt University 18
Diatherix Labs Enters into Research Agreement with Vanderbilt University Medical Center 19
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 20
BioReference Labs Enters into Co-Development Agreement with Vanderbilt-Ingram 21
Incyte Enters into Research Agreement with Vanderbilt University Medical Center 22
Boehringer Ingelheim Enters into Research Agreement with Vanderbilt University 23
BioAegis Therapeutics Enters into Agreement with Vanderbilt University and Northwestern University 24
Vanderbilt University Enters Into Research Agreement With GlaxoSmithKline For Obesity Drug 25
Baptist Memorial Health Care Enters Into Research Agreement With Vanderbilt University 26
Vanderbilt University Enters Into Agreement With Bristol-Myers Squibb To Develop Drugs For Parkinson’s Disease 27
Licensing Agreements 28
Appello Pharma Enters into Licensing Agreement with Vanderbilt University 28
Lundbeck Enters into Licensing Agreement with Vanderbilt University 29
La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 30
AstraZeneca Enters into Licensing Agreement with Vanderbilt University 31
Parker Hannifin Enters Into Licensing Agreement With Vanderbilt University For Exoskeleton Technology 32
Nanoferix Enters into Licensing Agreement with Vanderbilt University Center for Technology Transfer and Commercialization 33
Vanderbilt University – Key Competitors 34
Vanderbilt University – Key Employees 35
Vanderbilt University – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 38
Strategy And Business Planning 38
Apr 03, 2018: Vanderbilt University Medical Center Launches Nashville Biosciences 38
Mar 28, 2018: Deerfield Management and Vanderbilt University announce the launch of Ancora Innovation 39
Corporate Communications 41
May 15, 2018: Savoie named chief of Radiology s Cardiothoracic Imaging Section 41
Government and Public Interest 42
Aug 21, 2018: PCORI Board approves $85 million to support new studies on opioids, cancer and other high-burden conditions 42
Aug 16, 2018: Autoimmunity plays role in development of COPD, study finds 43
Jul 18, 2018: St. Baldrick’s foundation announces $19.1 million in grants to fund lifesaving childhood cancer research 44
Jul 10, 2018: Amino Acid Transporter May Offer Lung Cancer Patients New Hope 45
Jun 12, 2018: More than $28 million awarded for new atrial fibrillation research centers to improve patient outcomes 46
Jun 08, 2018: $8.1 million grant funds new center to research highly aggressive form of lung cancer 47
May 14, 2018: Study finds acetaminophen helps reduce acute kidney injury risk in children following cardiac surgery 49
May 07, 2018: New breakthrough paving the way for universal Ebola therapeutic 50
Apr 10, 2018: Aqueous humor, microRNAs and glaucoma 51
Mar 29, 2018: Study of mucus may help guide sinusitis treatment 52
Mar 15, 2018: New imaging approach offers unprecedented views of staph infection 53
Mar 06, 2018: Discovery by Vanderbilt-led group could lead to improved diabetes treatment 55
Mar 01, 2018: Study reveals safety signal from genes that mimic drugs 57
Feb 27, 2018: Multiple Types of Delirium in the ICU Indicate High Risk for Long-Term Cognitive Decline, Study Finds 58
Feb 14, 2018: A new target for neuroblastoma 59
Dec 13, 2017: Ives to Lead Opioid De-Prescribing Study with $9 Million PCORI Grant 60
Nov 14, 2017: Shining a light on the nervous system to thwart disease 61
Oct 12, 2017: VIGH receives federal grants to fight kidney disease 62
Aug 25, 2017: New research on Fragile X syndrome reinforces importance of early detection 63
Aug 24, 2017: Drug discovery efforts may lead to new Rett syndrome treatments 65
Aug 17, 2017: Discovery sheds light on protein key to nerve cells’ myelin sheath 67
Mar 17, 2017: New target for colorectal cancer 68
Mar 13, 2017: NIH-funded study helps explain how zebrafish recover from blinding injuries 69
Feb 03, 2017: Merryman wins $6M to address heart disease with arthritis drug, fund other research 70
Product News 71
Jun 12, 2017: Drug developed for arthritis could be first to stop heart valve calcification 71
May 03, 2018: Gene study spots clues to heart risk for statin patients 73
01/16/2018: VUMC Researchers find a Way to ‘starve’ Cancer 74
Other Significant Developments 75
Aug 23, 2018: FARE Clinical Network Adds Vanderbilt University Medical Center as New Center of Excellence 75
Aug 15, 2018: Healthcare Innovators professional society reaches member goal of 33 top industry executives for nationwide council 76
Jul 19, 2018: VUMC Diagnostic Laboratories expand, improve services 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78

List of Tables
Vanderbilt University, Pharmaceuticals & Healthcare, Key Facts 2
Vanderbilt University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vanderbilt University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vanderbilt University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vanderbilt University, Deals By Therapy Area, 2012 to YTD 2018 9
Vanderbilt University, Medical Devices Deals, 2012 to YTD 2018 10
Vanderbilt University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Deerfield Management and Vanderbilt University Form Joint Venture 13
Boehringer Ingelheim Enters into Agreement with Vanderbilt University 14
Bayer and Vanderbilt University Medical Center Enter into Research Agreement 15
Cancer Prevention Pharma Enters into Partnership with National Cancer Institute and Vanderbilt University Medical Center 16
Human Vaccines Project and Vanderbilt University Medical Center Enters into Agreement with Illumina 17
Boehringer Ingelheim Enters into Agreement with Vanderbilt University 18
Diatherix Labs Enters into Research Agreement with Vanderbilt University Medical Center 19
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 20
BioReference Labs Enters into Co-Development Agreement with Vanderbilt-Ingram 21
Incyte Enters into Research Agreement with Vanderbilt University Medical Center 22
Boehringer Ingelheim Enters into Research Agreement with Vanderbilt University 23
BioAegis Therapeutics Enters into Agreement with Vanderbilt University and Northwestern University 24
Vanderbilt University Enters Into Research Agreement With GlaxoSmithKline For Obesity Drug 25
Baptist Memorial Health Care Enters Into Research Agreement With Vanderbilt University 26
Vanderbilt University Enters Into Agreement With Bristol-Myers Squibb To Develop Drugs For Parkinson’s Disease 27
Appello Pharma Enters into Licensing Agreement with Vanderbilt University 28
Lundbeck Enters into Licensing Agreement with Vanderbilt University 29
La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 30
AstraZeneca Enters into Licensing Agreement with Vanderbilt University 31
Parker Hannifin Enters Into Licensing Agreement With Vanderbilt University For Exoskeleton Technology 32
Nanoferix Enters into Licensing Agreement with Vanderbilt University Center for Technology Transfer and Commercialization 33
Vanderbilt University, Key Competitors 34
Vanderbilt University, Key Employees 35
Vanderbilt University, Subsidiaries 36

List of Figures
Vanderbilt University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vanderbilt University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vanderbilt University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vanderbilt University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vanderbilt University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vanderbilt University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Vanderbilt University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vanderbilt University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vanderbilt University, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Vanderbilt University:製薬・医療:M&Aディール及び事業提携情報(Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆